South Korea

With the separation from its parent company now behind it, Samsung Bioepis celebrated its highest-ever annual revenues and outlined its vision of further growth.

A deal for the Duchenne muscular dystrophy treatment with Nxera is valued at up to $205m.

Generics Bulletin reviews global regulatory developments across the world.

European Commission approval positions Celltrion to streamline hospital workflows, with modelling suggesting millions in potential annual savings for healthcare systems.

Juby Jacob-Nara outlines her vision for expanding biosimilar uptake and leveraging policy changes to improve patient access.

Hikma has picked up the commercialization rights to half-a-dozen Celltrion biosimilars in the Middle East and North Africa, in the latest agreement between the pair.

Evaluate data show three biopharma initial public offerings on Western stock exchanges in the third quarter, up from two in Q2, all in the US. But China shows similar IPO activity.

With the looming spin-off on the horizon, Samsung Bioepis looks at planned product launches and geographic expansion to maintain its annual revenue growth.

Generics Bulletin reviews global regulatory developments across the world.

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Samsung Biologics will retain solely its significant CDMO business, eliminating a perceived conflict of interest, as it pursues an equity spin-off for its biosimilars business Samsung Bioepis.

South Korea’s Celltrion has doubled down on its efforts in further building its pipeline, eyeing a target of 22 commercialized products by 2030 while also aiming to submit INDs for 13 novel compounds.